Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

Since metastatic colorectal cancer (CRC) is a leading cause of cancer-related death, therapeutic approaches overcoming primary and acquired therapy resistance are an urgent medical need. In this study, the efficacy and toxicity of high-affinity inhibitors targeting antiapoptotic BCL-2 proteins (BCL-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Dis
Autors principals: Scherr, Anna-Lena, Mock, Andreas, Gdynia, Georg, Schmitt, Nathalie, Heilig, Christoph E., Korell, Felix, Rhadakrishnan, Praveen, Hoffmeister, Paula, Metzeler, Klaus H., Schulze-Osthoff, Klaus, Illert, Anna L., Boerries, Melanie, Trojan, Jörg, Waidmann, Oliver, Falkenhorst, Johanna, Siveke, Jens, Jost, Philipp J., Bitzer, Michael, Malek, Nisar P., Vecchione, Loredana, Jelas, Ivan, Brors, Benedikt, Glimm, Hanno, Stenzinger, Albrecht, Grekova, Svetlana P., Gehrig, Tobias, Schulze-Bergkamen, Henning, Jäger, Dirk, Schirmacher, Peter, Heikenwalder, Mathias, Goeppert, Benjamin, Schneider, Martin, Fröhling, Stefan, Köhler, Bruno C.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7568722/
https://ncbi.nlm.nih.gov/pubmed/33070156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-03092-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars